Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app beat superbugs? tanzania trial aims to find out

NCT ID NCT07393308

Knowledge-focused Sponsor: Muhimbili University of Health and Allied Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a mobile app that shows local antibiotic resistance patterns can help doctors in Tanzanian hospitals prescribe antibiotics more wisely. 300 prescribers will use either the app or standard paper charts. The goal is to see if the app improves antibiotic use and is accepted by doctors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mobile antibiogram application
What this could lead to
If it works, this could provide a practical tool to help doctors choose the right antibiotics, potentially slowing the spread of drug-resistant infections.
What could go wrong
This is an early-stage study focused on feasibility and acceptance, not on patient outcomes. The app may not change prescribing habits or reduce resistance in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria 1. All prescribers working in the selected tertiary referral hospitals 2. All prescribers owning smartphones 3. Prescribers who consent to take part in the study Exclusion criteria 1\. Temporarily employed prescribers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antimicrobial prescribing practices are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antimicrobial prescribing practices Antimicrobial resistance (AMR)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Benjamin Mkapa Hospital

    Dodoma, Tanzania

  • Mbeya Zonal Referral Hospital

    Mbeya, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.